Abstract 3990
Background
MET is a potential therapeutic target in advanced HCC; tepotinib is a highly selective MET inhibitor. Here we report final analysis results from a single-arm multicenter phase 2 study investigating the efficacy and safety of tepotinib in pts with sorafenib-treated advanced MET+ HCC (NCT02115373).
Methods
Adults with advanced MET+ HCC, Child-Pugh Class A, Eastern Cooperative Oncology Group performance status 0–1, and ≥4 weeks of prior sorafenib therapy were eligible for treatment. MET status was assessed by immunohistochemistry (2+ or 3+) and in-situ hybridization. Pts received tepotinib at the recommended phase 2 dose (RP2D) of 500 mg once-daily. The primary endpoint was progression-free survival status at 12 weeks; secondary endpoints included safety and other efficacy parameters.
Results
49 pts had received treatment; median (range) duration of therapy was 3.02 (0.03–16.49) months. Median (range) age was 66 (19–82) years and most patients were male (83.7%). The null hypothesis that the rate of progression-free subjects at 12 weeks is ≤ 15% has been rejected as 31/49 pts (63.3%; 90% confidence interval [CI]: 50.5, 74.7) were progression-free at 12 weeks; median PFS was 3.4 months (90% CI: 2.8, 4.2). Overall, there were 4/49 responders (8.2%; 90% CI: 2.8, 17.7; 1 complete and 3 partial responses). Median overall survival was 5.6 months (90% CI: 5.1, 8.2 months). The most common treatment-related adverse events (AEs) were peripheral edema (n = 32; 38.8%), fatigue (n = 10; 18.4%) and diarrhea (n = 16; 16.3%). 17 pts (34.7%) discontinued treatment due to AEs and 1 pt (2%) died from a treatment-related AE (hypoglycemic coma).
Conclusions
These data indicate that tepotinib has anti-tumor activity in pretreated MET+ advanced HCC and was well tolerated at the RP2D, with no new safety signals detected.
Clinical trial identification
NCT02115373.
Legal entity responsible for the study
Merck KGaA, Darmstadt, Germany.
Funding
Merck KGaA, Darmstadt, Germany.
Editorial Acknowledgement
Medical writing assistance (funded by Merck KGaA, Darmstadt, Germany) was provided by Martin Quinn, PhD of Bioscript Science (Macclesfield, UK).
Disclosure
C. Barone: Advisory board membership, Fee for presentation: Merck Serono. M. Wermke: Honaries: BMS, Novartis, Roche, Bayer, Glenmark, AstraZeneca; Travel reimbursements: AstraZeneca, BMS, MSD, Novartis, Glenmark; Research funding: Novartis, Pfizer. P. Merle: Advisory board member: Bayer, Ipsen, BMS. J.F. Blanc: Advisory board member: Bayer, Lilly Oncology, BMS, Onxeo, Esai, Ipsen. R. Bruns, J. Straub: Employee: Merck KGaA. C. Zhao: Employee: EMD Serono Inc. S. Faivre: Consultant, Clinical trials grants: Blueprint, BMS, Bayer Pharma, Eli Lilly, Ipsen, Merck Serono, MSD, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract